An in-progress open-label multi-centre study (SAILOR) evaluating whether a steroid-free immunosuppressive protocol based on ATG induction and a low tacrolimus dose reduces the incidence of new onset diabetes after transplantation

摘要

BackgroundCorticosteroids and calcineurin inhibitors (CNIs) are included in renal transplantation immunosuppressive protocols around the world. Well-known side effects are associated with the use of these drugs, including new onset of diabetes after transplantation (NODAT). Long-term patient survival rates are lower among patients with NODAT. The optimal immunosuppressive protocol would therefore include not using corticosteroids and minimization of CNI use.